Minerva Neurosciences (NERV) Stock Price, Quote, News & History | Benzinga

Minerva Neurosciences Inc (NERV) Stock Price, Quote, News & History

NERVNASDAQ

Trade with Public

Trade with Public

$4.57

0.0851.9%

Last update: Sep 2, 3:41 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$4.50

Close

-

Volume / Avg.

35.65K / 250.95K

Day Range

$4.46 - $4.60

52 Wk Range

1.93 - 12.46

Market Cap

$217.97M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

3.85%

Days to Cover

11.76

Recent Minerva Neurosciences, Inc News

This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.

Avi Kapoor

Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial

Minerva Neurosciences Inc (NASDAQ:NERV) shares are climbing Tuesday after the company announced up to $200 million in funding to support development of roluperidone for schizophrenia.

Evette Mitkov

US Stocks Mixed; Coca-Cola Posts Upbeat Earnings

Avi Kapoor

Roche's Ocrevus Subcutaneous Gets European Commission Nod

Roche (OTC: RHHBY) announced that the European Commission has granted marketing authorization to the subcutaneous formulation of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) drug Ocrevus (ocrelizumab).

Zacks

Ultragenyx Posts New Data From Bone Disease Study

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), along with partner Mereo BioPharma (MREO), announced new positive 14-month data from the phase II portion of the phase II/III Orbit study evaluating setrusumab (UX143) in patients with osteogenesis imperfecta.

Zacks

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-26.17M

Investing Cash Flow (TTM)

-50.13M

Financing Cash Flow (TTM)

85.70M

Free Cash Flow (TTM)

-26.17M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

9.40M

Analyst Trends and Forecast

1

Mar

0

0

0

0

Apr

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$138.64M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-806.25%

Earnings Yield % (FWD)

-9.38%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$4.47

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$24.65M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$4.50

Close

-

Volume / Avg.

35.65K / 250.95K

Day Range

$4.46 - $4.60

52 Wk Range

1.93 - 12.46

Market Cap

$217.97M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

3.85%

Days to Cover

11.76

About

Sector

Health Care

Industry

Biotechnology

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candid...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Minerva Neurosciences (NERV) stock?

A

You can purchase shares of Minerva Neurosciences (NASDAQ:NERV) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Minerva Neurosciences (NERV) competitors?

A

Other companies in Minerva Neurosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Minerva Neurosciences (NERV) stock?

A

Minerva Neurosciences has a consensus price target of $10.33.

Q

What is the current price for Minerva Neurosciences (NERV)?

A

The stock price for Minerva Neurosciences (NASDAQ: NERV) is $4.565 last updated September 2, 2026 at 3:41 PM EDT.

Q

Does Minerva Neurosciences (NERV) pay a dividend?

A

There are no upcoming dividends for Minerva Neurosciences.

Q

When is Minerva Neurosciences (NASDAQ:NERV) reporting earnings?

A

Minerva Neurosciences does not have any upcoming earnings scheduled.

Q

Is Minerva Neurosciences (NERV) going to split?

A

There is no upcoming split for Minerva Neurosciences.

Q

What sector and industry does Minerva Neurosciences (NERV) operate in?

A

Minerva Neurosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.